laboratory, and radiographic markers of autoimmunity, some patients elude formal diagnosis.
In recent years, research into the basic immunological processes underlying many of these syndromes has revealed several common pathophysiologic mechanisms. At the most basic level, all autoimmune disorders of the nervous system are caused by an adaptive immune response directed against an antigen within the nervous system. Several overlapping categories of autoimmune neurological disease-including primary autoimmune, paraneoplastic, and parainfectiousare mediated by the abnormal adaptive immune response. The pathologic response is induced by either autoantigens (self-antigens) or foreign antigens. Autoantigens recruit the adaptive immune system in autoimmune and paraneoplastic disorders. In paraneoplastic disorders, which occur in the context of a neoplasm, the immune response is directed against neuronal antigens that are ectopically expressed by the tumor (e.g., limbic encephalitis caused by the expression of the ANNA-1 (Hu) antigen by small cell lung cancer).
2
Parainfectious conditions are mediated by an abnormal or enhanced immune response triggered by a foreign antigen (e. g., Guillain-Barré syndrome caused by molecular mimicry resulting in the production of antiganglioside antibodies).
3
Some conditions, such as anti-NMDA receptor encephalitis, can be autoimmune (without an associated neoplasm), paraneoplastic (related to ovarian teratoma), 4 or parainfectious (as in post-HSV anti-NMDA receptor encephalitis).
5
Although the source of the inciting antigen may vary, the underlying mechanism of immune dysfunction is likely the same in each of these settings. Iatrogenic autoimmune neurologic disorders are now garnering increased recognition, given the rise in the incidence of these disorders as a result of powerful immune-activating therapies for oncologic indications. 6 With the increasing use of immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cells for the treatment of cancer, the incidence of these disorders is likely to continue to rise in coming years. As such, many of these disorders are better classified not by the specific autoantigen involved but rather by their common underlying pathogenic mechanisms of immune dysfunction. This is important because the presence of certain autoantibodies, such as anti-GAD65 or anti-ANNA-1 (Hu), can often be observed in several different autoimmune neurologic syndromes 3, 7 and in certain cases may simply be a marker for an autoimmune process with an unknown pathologic target (e.g., anti-thyroid peroxidase [TPO] in Hashimoto's encephalopathy 8, 9 ). Additionally, as described earlier, more than one pathogenic mechanism can give rise to the same clinical syndrome. 3 As an example, limbic encephalitis can be caused by autoantibodies against NMDA receptor and T-cell-mediated cytotoxicity associated with anti-ANNA1 (Hu) antibodies. Ultimately, though, the key to this classification scheme, based on mechanism of underlying immune dysfunction, is that it emphasizes early disease-modifying treatment above definitive diagnosis. Furthermore, clinical syndromes that elude formal diagnosis can at the very least be characterized immunologically to guide a rational approach to empiric therapy in the ICU.
Immune mechanisms and related pathology that are implicated in autoimmune disorders of the nervous system can be classified into disorders of T-cell-mediated pathology, autoantibody-mediated pathology, granulomatous inflammation, autoinflammatory pathology, and iatrogenic activation of a specific immune process or target (►Table 1).
Iatrogenic Autoimmunity
Iatrogenic autoimmunity is not a novel concept. Drug-induced lupus is a well-established adverse effect of several nonimmunomodulatory drugs, including procainamide, hydralazine, and minocycline. The incidence of iatrogenic autoimmunity has risen with the introduction of immunomodulatory therapeutics, including interferon-α, tumor necrosis factor-α (TNFα) inhibitors and, most recently, checkpoint inhibitors and genetically altered CAR-T cells. 6 Despite the risk of development of systemic and CNS autoimmune disorders, the use of immunomodulatory therapies has become the standard of care in patients with autoimmune disorders and for many oncologic indications, such as advanced melanoma. Thus, understanding and early recognition of their CNS-related adverse effects will be imperative. For example, interferon-α has been linked to the exacerbation of psoriasis and sarcoidosis 10 and the development of autoimmunity manifesting as vasculitis, inflammatory arthritis, and drug-induced lupus, among others. TNFα inhibitors, which are typically used for the management of rheumatoid arthritis and inflammatory bowel disease, carry an increased risk for CNS and peripheral nervous system demyelination 11,12 and drug-induced lupus.
13,14
Immune checkpoint inhibitors are a novel class of therapeutics designed to target the inhibitory pathways in the immune system that maintain self-tolerance and modulate the immune response.
15 Cytotoxic T-lymphocyte-associated antigen 4
(CTLA-4) was the first clinically targeted immune checkpoint receptor and functions by regulating the central expansion of T cells. The interaction of T-cell-expressed CTLA-4 with CD80 or CD86 on antigen-presenting cells blocks T-cell costimulation and abrogates an activated T-cell response. Inhibition of CTLA-4 thus overcomes a block in costimulatory signals that are required for activation of both naive T cells and resting clones, harnessing the host's native immune response against cancer. 15, 16 Another clinically relevant immune checkpoint receptor, programmed cell death protein 1 (PD-1), and its ligand (PD-L1) have been targeted to prevent the inhibition of cytotoxic T cells via upregulated ligands PD-L1 and PD-L2 in the tumor microenvironment. 15 The checkpoint inhibitors ipilimumab (human antibody to CTLA-4) and pembrolizumab and nivolumab (PD-1 antagonists) and combination strategies with immunotherapy have offered cancer patients durable disease control. However, they have also unmasked unique neurological toxicities that can range from minor headaches and confusional states to severe disabling demyelinating disorders and immune-mediated encephalitis. 17 The incidence of immunerelated neurological adverse events with the use of checkpoint inhibitors is reported to be as high as 1%. 18 Checkpoint inhibitors may trigger the immune response against the pituitary gland 19 and specific neuronal antigens, leading to autoimmune 21 Ongoing development and use of checkpoint inhibitors will necessitate clinicians to become even more vigilant in their evaluation of adverse neurologic events and assessing for induced autoimmunity, especially given the broad spectrum of possible clinical syndromes (►Table 2). CAR-T cells are genetically modified T cells that have a fabricated antigen receptor from multiple sources engineered to a specific target cell antigen. A patient's own cells are isolated, genetically modified, cloned, and reinfused to redirect T-cell specificity to a specific tumor-associated antigen. 22 New generations of CAR-T cells have incorporated a costimulatory domain that offer a potentially durable treatment response but leave patients susceptible to potential side effects for years following therapy. Cytokine release syndrome (CRS) is the most common side effect encountered with CAR-T-cell therapy, and results from T-cell activation, proliferation, and production of endogenous cytokines.
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Symptoms can span fever and flu-like syndromes to systemic shock and multiorgan failure including profound neurotoxicity. These neurologic symptoms may range from headache and confusion to frank delirium, aphasia, seizures, and, in severe cases, coma. 23, 24 The mechanism for these immunemediated side effects are still being elucidated, but organ damage may occur by autoimmune mechanisms when CAR-T cells cross-react with native host antigens. 
Other Mechanisms of Autoimmunity and Neuroinflammation
Granulomatous inflammation is a form of chronic inflammation defined by the presence of histiocytes (activated macrophages), which engage in interaction with CD4þ T cells. The histiocytes may coalesce to form multinucleated giant cells. Examples of granulomatous diseases include sarcoidosis and giant cell arteritis (GCAs; ►Table 1). Autoinflammatory disorders are driven by dysregulated innate rather than adaptive immunity. 29 In certain conditions, the mechanism of autoimmunity cannot be elucidated and is reported here as not otherwise specified (NOS).
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Autoantigens in the Nervous System and Associated Disorders
Antigens targeted by autoantibodies and T cells in primary neurologic autoimmune disorders are expressed by glia or neuronal cells. Examples of diseases characterized by glial autoimmunity include neuromyelitis optica spectrum disorders (NMOSD) mediated by antibodies to aquaporin-4 (AQP4), 31 conditions mediated by antibodies to myelin oligodendrocyte glycoprotein (MOG), 32 and a steroid-responsive meningoencephalomyelitis associated with antibodies to glial fibrillary acidic protein (GFAP). 33 The spectrum of conditions associated with neuronal autoimmunity is much wider and depends on the cell types that are targeted, function of the targeted antigen, and immunopathogenic mechanisms that are recruited by T cells or autoantibodies. Cognitive impairment with leukoencephalopathy (ganglionopathy), myasthenia gravis (MG), and Lambert-Eaton myasthenic syndrome (►Table 3). The majority of the listed conditions have been associated with several autoantibodies. Conversely, the same antibody can cause different syndromes; for example, anti-ANNA-1 (Hu) antibody has been associated with limbic encephalitis and sensory ganglionopathy. As our understanding of the basic pathologic mechanisms underlying autoimmunity continues to grow, it is very likely that this approach will become of increasing importance in the treatment of acute neuroinflammatory disorders. At present, this approach will hopefully be of help in guiding treatment decisions in these otherwise seemingly "datafree" zones of critical care medicine. For this reason, we will organize our discussion of these disorders on the pathophysiology of the underlying immune dysfunction, workup strategies, and available interventions. While there is an attempt to cluster these groups of disorders based on immunological processes involved, we do recognize that frequently multiple immunological pathways are implicated and multiple classes of interventions may be effective. Treatment strategies will focus on the spectrum of potential risk/benefit ratios for currently available immunologic therapies. Unfortunately, these disorders frequently remain untreated or undertreated because of difficulties with establishing the diagnosis, especially in cases when histopathological evaluation is essential. We suggest organizing these disorders based on the predominant pathophysiology of the underlying immune dysfunction, diagnostic strategies, and available interventions. This approach allows for the possibility of rapid interventions with empiric therapies in cases where diagnosis remains elusive.
Epidemiology
Autoimmune disorders of the nervous system are generally diagnosed at a younger age than other disorders of the nervous system warranting ICU level care, such as infectious or vascular injuries. However, all age groups can be equally affected. Certain disorders are well known to have a preponderance for a particular sex; NMO, multiple sclerosis (MS), Susac's syndrome, younger patients with MG, Sjögren's syndrome, 37 Behçet's disease in the United States and northern Europe, 31, 38 and GCA are all more common in women than in men, whereas older patients with MG, chronic inflammatory demyelinating polyneuropathy, acute disseminated encephalomyelitis, 39 Guillain-Barré syndrome, and IgG4-related disease (IgG4RD) 40 are all slightly more common in men. No gender predilection exists in sarcoidosis or primary angiitis of the central nervous system (PACNS).
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Diagnostic Strategy
The differential diagnosis of new-onset neurologic dysfunction in the ICU is almost always first described generically as toxic/metabolic, infectious, neoplastic, primary vascular, or inflammatory (autoimmune/parainfectious/paraneoplastic). Autoimmune disorders are suspected when the disease course is subacute (progression over a course of <3 months); there is evidence of inflammation; and toxic, metabolic, hereditary disorders (e.g., mitochondrial diseases, inborn errors of metabolism), infectious, and primary neoplastic processes are less likely or have been excluded. 7 The course of autoimmune neurologic disease may be monophasic, relapsing-remitting, Autoimmune disorders of the nervous system may be limited to (e.g., isolated neurosarcoidosis) and/or specific for the nervous system (e.g., MS) or may be a manifestation of a systemic disease (e.g., Sjögren syndrome). 43 They can affect any neurological domain and frequently have multifocal presentations. Occasionally, well-defined clinical syndromes can be identified and these are extremely helpful; examples are listed in ►Table 3. More frequently though, the clinical findings are nonspecific and additional evidence is sought through diagnostic testing.
All patients in the ICU should undergo a routine laboratory workup to rule out alternative, noninflammatory conditions, and to look for evidence of systemic medical conditions that may be associated with or underlying the presenting neurologic syndrome. 37, 43, 44 For example, patients with neurosarcoidosis with hypothalamic involvement may have evidence of hormonal dysfunction, and a normocytic anemia may be seen as a consequence of chronic systemic inflammation in several different rheumatologic disorders. 29 These medical conditions may also affect the treatment decisions. ►Table 4 lists a set of basic screening laboratories that can be helpful to rule out alternative diagnoses or support the diagnosis of autoimmune dysfunction. There is an ongoing effort to establish immunologic biomarkers that could serve as an aid in the early identification of iatrogenic complications of immune checkpoint inhibitors and CAR-T cells. One of the first diagnostic studies obtained in most cases is some form of neuroimaging. Although head computed tomography (CT) is often the most rapidly attainable neuroimaging study, the diagnostic yield of this study in evaluating suspected neuroinflammatory disorders is very poor. CT angiography and postcontrast scans are somewhat more useful, particularly for cases of suspected CNS vasculitis. Magnetic resonance imaging of the brain (and often spine) with and without gadolinium has become the cornerstone of advanced neurological workup in the ICU. Patterns of T2/FLAIR abnormalities, restricted diffusion, contrast enhancement, and perfusion sequences may be specific for certain infectious, toxic, or inflammatory conditions (►Table 5). . 48 Further studies are still needed to validate the positive and negative predictive value of abnormalities of glucose metabolism in FDG-PET/CT for the diagnosis of autoimmune encephalitis. 49 ►Table 6 describes additional imaging modalities and possible diagnostic conclusions to which these studies may lead. An important test in the workup of inflammatory disorders of the nervous system is the lumbar puncture, and the diagnostic value of cerebrospinal fluid (CSF) analysis in CNS dysfunction cannot be emphasized enough. ►Table 7 lists initial CSF studies that should be requested in all patients with suspected inflammatory neurologic disorders. CSF inflammation is most frequently defined by the presence of one or more of the following: pleocytosis (>5 white blood cells), elevated protein (>50 mg/dL), the presence of oligoclonal bands (OCBs; >1 or higher dependent on local laboratory thresholds), and an elevated IgG index (>0.66). Hypoglycorrhachia (glucose <45 mg/dL) is typically seen in infectious (bacterial, fungal) and neoplastic conditions (leptomeningeal carcinomatosis), but can be observed in some inflammatory disorders (typically neurosarcoidosis, and also in PACNS and neuro-Behçet's disease).
50 CSF cytology and flow cytometry may provide further insight into the pathogenesis of the underlying disease process, and can be helpful in identifying neoplastic or therapeutically induced etiologies. It is important to recognize that often the only marker of CNS inflammation is the presence of autoantibodies or OCBs, and that even in the absence of elevated protein or pleocytosis, these findings may be signs of pathology. 52 The classic example is MS; however, OCBs in the CSF are not unique to MS and are simply a marker of the intrathecal production of immunoglobulins. Importantly, whenever CSF is sent for OCB analysis, there should be a parallel investigation of serum with a report on the relative band patterns in the CSF and serum to confirm the presence of intrathecal oligoclonal immunoglobulin production. 53 Quantitative IgG analysis (i.e., IgG index) is an informative complementary test but is not considered a substitute for qualitative IgG assessment (OCBs), which has higher sensitivity and specificity. In addition to CSF cell counts with differential, cellular responses can be evaluated by analysis of T-cell subsets and their CD4/CD8 ratio. 54 This is, however, of limited value, and the normal values are not standardized (►Table 8). As discussed earlier, many autoantibodies serve as biomarkers of disease mediated by T cells. Electroencephalography is rarely specific but often very informative diagnostically in evaluating patients with altered level of consciousness or localizing pathologic regions within the brain. Occasionally, certain findings may be suggestive of specific disease processes (see ►Table 6 for details).
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2,9 Additional investigations may be required to narrow down the differential diagnosis, establish a definitive diagnosis, or determine the extent of a systemic disease (►Table 6). Whole-body PET/CT may also be used to determine appropriate sites for diagnostic biopsy in patients with multisystem involvement. Autoimmune Encephalitis in Critical Care Rubin et al. 813
Often the workup of neurologic disease yields only nonspecific markers of inflammation without providing a specific diagnosis, in which case stereotactic brain biopsy may be required to further narrow the pathologic process and guide treatment. When considering CNS biopsy, the potential diagnostic benefit must be weighed against the risk of permanent neurologic injury. With that said, in patients with rapidly progressive neurologic deterioration of uncertain etiology, often the value is sufficiently high and morbidity sufficiently low to justify the use of biopsy. 55 In general, targets for biopsy should be in regions of active disease involvement on neuroimaging. When the area of active involvement is inaccessible, the potential diagnostic yield of biopsy drops considerably and the utility of such an intervention should be further considered. When feasible, brain and/or meningeal biopsy yields invaluable information regarding the nature of the inflammatory response, the underlying cellular/immune process, and the microstructural distribution of the inflammation, all of which can have significant impact on the choice of therapy. Demonstration of characteristic histopathological findings is the method of choice for making definitive diagnosis of vasculitis, sarcoidosis, IgG4RD, and neoplasm.
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Treatment Options
In the ICU setting, the clinical examination and diagnostic workup must be focused on identifying specific pathophysiologic processes that allow for early targeted treatment, rather than solely aimed at securing a specific diagnosis. The balance between diagnostic confidence, the risk of disease progression, and the risks of treatments will ultimately define individual patient care. No large randomized controlled trials have been performed in patients with neuroinflammatory conditions, and may significantly contribute to secondary sequelae such as opportunistic infections. It is important to realize that this is true for other widely accepted indications for these medications including immune suppression in organ transplantation. The treatment of immunologic diseases of the brain is not limited to immunomodulation but includes the supportive management of associated secondary symptoms. The clinical course of patients with autoimmune neurologic disorders is frequently complicated by periods of both agitation and paroxysmal sympathetic hyperactivity, each of which may be superimposed on a backdrop of often-profound encephalopathy. 62, 63 There is little data available to guide clinicians about the most appropriate ways to manage these difficult and often refractory symptoms, which frequently lead to major morbidity and mortality for otherwise reversible disorders. Our recommendations for pharmacological interventions are based mainly on experiences with patients who have suffered traumatic brain injury, stroke, and subarachnoid hemorrhage. [64] [65] [66] Overall, we advocate for nonpharmacologic measures, such as promoting the presence of family at the bedside, reinforcement of appropriate cues to promote a normal circadian rhythm, keeping familiar sights and sounds with personal pictures and music in the room, and other delirium precautions. In the event these environmental interventions are insufficient, pharmacological interventions are instituted. Our recommended treatment options are presented in ►Table 9. The interventions are grouped into three different sections, which are at times difficult to separate clinically: paroxysmal sympathetic hyperactivity, agitation, and shivering control during aggressive temperature management.
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Finally, many of these disorders are paraneoplastic, occurring in the setting of neoplasia (malignant or benign tumors). These lesions are frequently small but need to be identified and treated rapidly to decrease the antigen load.
2 Testing can often take weeks to occur, whereas neurologic deterioration can occur over hours. For example, surgical resection of an ovarian teratoma identified on imaging in a patient with a clear-cut clinical syndrome of anti-NMDA receptor encephalitis should not be delayed while awaiting the results of serology. Cases of paraneoplastic autoimmune neurologic disorders require multidisciplinary therapy plans developed by neurologists, oncologists, radiation therapists, and surgeons. Iatrogenic autoimmune complications of checkpoint inhibitors and CAR-T-cell therapy should always be managed in collaboration with the primary oncologist. Treatment of immune-related adverse events (irAEs) of checkpoint inhibitors includes interruption or permanent discontinuation of their use and may require corticosteroids and possibly even additional immunosuppressants, such as TNFα inhibitors and mycophenolate mofetil. 70 As described earlier, the most prominent irAE of CAR-T-cell therapy is CRS, which is treated with the recombinant IL-6 receptor antagonist tocilizumab. The neurologic toxicities of CAR-T-cell therapy are generally also treated with corticosteroids, which have a superior bloodbrain barrier penetration to tocilizumab and may also act on pathologic immune pathways unrelated to CRS.
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Treatment Risks
Treatment with immunomodulatory agents incurs a significant risk for infection and other systemic side effects. The potential risks of adverse reactions can be minimized by screening evaluations, patient monitoring, and preventative measures. Baseline and screening laboratory testing that should be obtained before introducing immunomodulatory agents is listed in ►Table 10, and preventative measures for infectious and noninfectious complications are outlined based on specific toxicities of individual medications in ►Table 11. ). However, routine vaccinations against influenza, Streptococcus pneumoniae, and zoster are frequently avoided during the period of acute illness, as they may conceivably worsen immunologic disease.
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Glucocorticoids and many immunomodulators increase the risk for Pneumocystis jiroveci pneumonia (PJP); this risk is more relevant in chronically immune suppressed patient, but antibiotic prophylaxis is frequently considered, in particular as patients started on steroids in the ICU often will require a prolonged taper.
►Table 11 lists available acute immunomodulatory regimens and associated prophylaxis. It is important to recognize that, while there are limited data guiding the use of these medications, the risk of withholding potentially efficacious treatment may outweigh risks associated with therapeutic agents for rapidly deteriorating patients.
Frequently, screening laboratory tests are positive, but immunologic treatment is still given; in these cases, additional antimicrobials, an infectious disease consultation, or additional discussions with the family regarding relative risks and benefits may be warranted. For example, JC virus (JCV) serologies are often positive prior to initiation of immunemodifying therapy, in which case the JCV antibody index may be useful to assess the relative risk of progressive multifocal leukoencephalopathy (PML) in the individual patient (JCV antibody index >1.5 indicates an increased risk for PML).
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The risk-benefit ratio of any immunosuppressive drug should be discussed with each patient and their family. Given their potential for significant toxicity, obtaining informed consent is required for certain immunosuppressants, such as cyclophosphamide, rituximab, and natalizumab.
Autoimmune neurologic disease is common in the younger people, and family planning should be addressed in each patient of reproductive age. Fertility preservation measures should be instituted in every patient in whom cyclophosphamide use is considered. Adjustment or discontinuation of immunosuppression should be considered before a planned pregnancy. Certain treatments are compatible with pregnancy, including glucocorticoids, IVIG, plasmapheresis, and azathioprine up to 2 mg/kg/day. 74 TNFα inhibitors are considered reasonably safe within first and second trimester and during lactation. Methotrexate, mycophenolate mofetil, and cyclophosphamide must be discontinued before conception due to proven teratogenicity (pregnancy category D and X). Most biologic agents have limited documentation on safe use in pregnancy and should be discontinued or replaced by other medication before conception. Immunologic interventions may counteract the primary treatment goal in cases of iatrogenic autoimmune CNS disorders, where the initial treatment with CAR-T-cell therapy produces a robust tumor lysis response at the cost of CNS toxicity. In these cases, anti-IL-6 therapies such as tocilizumab may be employed first, but ultimately corticosteroids may be required to dampen and, as a result, potentially eliminate the therapeutic CAR-T-cell response. 25 Finally, it should be recognized that immunologic interventions often affect the yield of future diagnostic studies. For example, treatment with IVIG will make the interpretation of future serologic studies particularly difficult, and treatment with glucocorticoids can significantly decrease the diagnostic yield of tissue biopsy of certain inflammatory and neoplastic lesions. For this reason, it is reasonable to collect extra serum and necessary tissue biopsies prior to the initiation of therapy.
Conclusion
Autoimmune neurologic disorders in the critical care unit often cause significant morbidity and mortality, and are associated with prolonged and expensive ICU stays. Fortunately, if treated rapidly, these are potentially reversible disorders. Focusing early interventions on appropriate mechanism-based therapy centered on suspected etiology with currently available immunomodulatory agents is essential to prevent irreversible neurologic injury and secure the best chance of a good outcome. Research aimed at expanding our understanding of the basic pathophysiology of these diseases will hopefully allow for more targeted interventions in years to come.
